The Purinergic System As a Target for the Development of Treatments for Bipolar Disorder

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2022 Jul 13

PMID 35829960

Authors

Maria Carolina Bittencourt Goncalves

Roberta Andrejew

Carolina Gubert

Affiliations

Soon will be listed here.

Abstract

The neurobiological and neurochemical mechanisms underlying the pathophysiology of bipolar disorder are complex and not yet fully understood. From circadian disruption to neuroinflammation, many pathways and signaling molecules are important contributors to bipolar disorder development, some specific to a disease subtype or a cycling episode. Pharmacological agents for bipolar disorder have shown only partial efficacy, including mood stabilizers and antipsychotics. The purinergic hypothesis for bipolar disorder emerges in this scenario as a promising target for further research and drug development, given its role in neurotransmission and neuroinflammation that results in behavioral and mood regulation. Here, we review the basic concepts of purinergic signaling in the central nervous system and its contribution to bipolar disorder pathophysiology. Allopurinol and novel P2X7 receptor antagonists are promising candidates for treating bipolar disorder. We further explore currently available pharmacotherapies and the emerging new purinergic targets for drug development in bipolar disorder.

Citing Articles

Uric Acid as a Biomarker for Mood Disorders: A Comparative Study of Blood Uric Acid Levels Correlating With the Symptom Severity and Treatment Response.

Immanuel S, Kaki A, Jetty R, Vupputuri S, K V R, R A Cureus. 2024; 16(8):e66784.

PMID: 39268307 PMC: 11392049. DOI: 10.7759/cureus.66784.

P2X7 receptor inhibition alleviates mania-like behavior independently of interleukin-1β.

Goloncser F, Baranyi M, Tod P, Maacz F, Sperlagh B iScience. 2024; 27(3):109284.

PMID: 38444608 PMC: 10914489. DOI: 10.1016/j.isci.2024.109284.

Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.

Daniels S, Boison D Neuropharmacology. 2023; 241:109756.

PMID: 37820933 PMC: 10841508. DOI: 10.1016/j.neuropharm.2023.109756.

Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.

Machado-Vieira R, Courtes A, Zarate Jr C, Henter I, Manji H Front Neurosci. 2023; 17:1228455.

PMID: 37592949 PMC: 10427509. DOI: 10.3389/fnins.2023.1228455.

References

Price J, Drevets W . Neurocircuitry of mood disorders. Neuropsychopharmacology. 2009; 35(1):192-216. PMC: 3055427. DOI: 10.1038/npp.2009.104. View

Scaini G, Valvassori S, Diaz A, Lima C, Benevenuto D, Fries G . Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings. Braz J Psychiatry. 2020; 42(5):536-551. PMC: 7524405. DOI: 10.1590/1516-4446-2019-0732. View

Maletic V, Raison C . Integrated neurobiology of bipolar disorder. Front Psychiatry. 2014; 5:98. PMC: 4142322. DOI: 10.3389/fpsyt.2014.00098. View

Sigitova E, Fisar Z, Hroudova J, Cikankova T, Raboch J . Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci. 2016; 71(2):77-103. DOI: 10.1111/pcn.12476. View

Kim Y, Santos R, Gage F, Marchetto M . Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges. Front Cell Neurosci. 2017; 11:30. PMC: 5306135. DOI: 10.3389/fncel.2017.00030. View

Rosa A, Sanchez-Moreno J, Martinez-Aran A, Salamero M, Torrent C, Reinares M . Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007; 3:5. PMC: 1904447. DOI: 10.1186/1745-0179-3-5. View

Perlis R . Misdiagnosis of bipolar disorder. Am J Manag Care. 2005; 11(9 Suppl):S271-4. View

Patel R, Shetty H, Jackson R, Broadbent M, Stewart R, Boydell J . Delays before Diagnosis and Initiation of Treatment in Patients Presenting to Mental Health Services with Bipolar Disorder. PLoS One. 2015; 10(5):e0126530. PMC: 4439113. DOI: 10.1371/journal.pone.0126530. View

Fountoulakis K, Kasper S, Andreassen O, Blier P, Okasha A, Severus E . Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012; 262 Suppl 1:1-48. DOI: 10.1007/s00406-012-0323-x. View

10.

Jones G, Vecera C, Pinjari O, Machado-Vieira R . Inflammatory signaling mechanisms in bipolar disorder. J Biomed Sci. 2021; 28(1):45. PMC: 8194019. DOI: 10.1186/s12929-021-00742-6. View

11.

Arcuino G, Lin J, Takano T, Liu C, Jiang L, Gao Q . Intercellular calcium signaling mediated by point-source burst release of ATP. Proc Natl Acad Sci U S A. 2002; 99(15):9840-5. PMC: 125036. DOI: 10.1073/pnas.152588599. View

12.

Illes P, Burnstock G, Tang Y . Astroglia-Derived ATP Modulates CNS Neuronal Circuits. Trends Neurosci. 2019; 42(12):885-898. DOI: 10.1016/j.tins.2019.09.006. View

13.

Di Virgilio F, Schmalzing G, Markwardt F . The Elusive P2X7 Macropore. Trends Cell Biol. 2018; 28(5):392-404. DOI: 10.1016/j.tcb.2018.01.005. View

14.

Pelegrin P . Many ways to dilate the P2X7 receptor pore. Br J Pharmacol. 2011; 163(5):908-11. PMC: 3130938. DOI: 10.1111/j.1476-5381.2011.01325.x. View

15.

Pankratov Y, Lalo U, Verkhratsky A, North R . Vesicular release of ATP at central synapses. Pflugers Arch. 2006; 452(5):589-97. DOI: 10.1007/s00424-006-0061-x. View

16.

Zhang Z, Chen G, Zhou W, Song A, Xu T, Luo Q . Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol. 2007; 9(8):945-53. DOI: 10.1038/ncb1620. View

17.

Imura Y, Morizawa Y, Komatsu R, Shibata K, Shinozaki Y, Kasai H . Microglia release ATP by exocytosis. Glia. 2013; 61(8):1320-30. DOI: 10.1002/glia.22517. View

18.

Burnstock G . Introduction to Purinergic Signalling in the Brain. Adv Exp Med Biol. 2020; 1202:1-12. DOI: 10.1007/978-3-030-30651-9_1. View

19.

Burnstock G . Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci. 2006; 27(3):166-76. DOI: 10.1016/j.tips.2006.01.005. View

20.

Burnstock G, Kennedy C . P2X receptors in health and disease. Adv Pharmacol. 2011; 61:333-72. DOI: 10.1016/B978-0-12-385526-8.00011-4. View